Latest Concord Biotech stock price

Concord Biotech P/E Ratio

CONCORDBIO • P/E ratio trend, valuation band, and sector comparison — all formatted to support journal-based trading review.
Current P/E Ratio
44.28
High Valuation
Very High - High growth expectations or significantly overvalued

Current Valuation Metrics

P/E Ratio 44.28
Current Price ₹1345.60
EPS (TTM) ₹35.52
Exchange NSE

Valuation Signal

Signal Overvalued
Historical Avg 39.91
Historical Range 32.39 - 47.43
Percentile 50.0%

Sector Context

Sector Average 57.47
Sector Median 35.38
Sector Rank #11 of 88
Sector Percentile 12.5%

Earnings Breakdown (TTM)

TTM EPS ₹32.81
Sept 2025 ₹6.03
Mar 2025 ₹13.42

Key P/E Ratio Insights for Concord Biotech

  • Stock appears overvalued with PE of 44.28, suggesting caution for new investments
  • Trading at discount to sector average PE of 57.47

View the CONCORDBIO equity price for detailed stock performance.

P/E Ratio Historical Trend for Concord Biotech

Historical P/E ratio trend based on annual earnings data. Lower P/E ratios may indicate undervaluation, while higher ratios suggest growth expectations.

Historical P/E Ratio Data

Year P/E Ratio EPS (₹) Year-end Price (₹) Exchange Valuation
2024 47.43 31.19 ₹1479.40 NSE High
2023 32.39 29.11 ₹942.80 NSE High

Sector P/E Ratio Comparison

Comparing Concord Biotech with other companies in Healthcare sector
Sector Average
57.47
Sector Median
35.38
Lowest P/E
9.01
Highest P/E
515.32
Companies
88
Company Symbol P/E Ratio Market Cap (₹ Cr) Valuation
Fermenta Biotech FERMENTA 9.01 ₹1,010 Low
Natco Pharma NATCOPHARM 10.8 ₹17,006 Low
Mohini Health & Hygiene MHHL 11.84 ₹69 Low
Lincoln Pharmaceuticals LINCOLN 12.02 ₹974 Low
QMS Medical Allied Servi… QMSMEDI 12.82 ₹177 Low
Take Solutions TAKE 13.15 ₹638 Low
Venus Remedies VENUSREM 14.27 ₹995 Low
Royal Sense ROYAL 14.5 ₹96 Low
Bliss GVS Pharma BLISSGVS 16.62 ₹1,973 Moderate
RPG Life Sciences RPGLIFE 17.94 ₹3,861 Moderate